• Coviderm

    We are seeking a partner to conduct POC preclinical work followed by a Phase I/II trial in order to adapt our immunotherapy technology platform for the treatment of SARS-CoV-2 infection.

    Both trials will target, in addition to the spike protein already targeted by antibody vaccines, several conservative proteins of the ORF1ab region of SARS-CoV-2, with the primarily endpoint of generating long lasting memory T-cell immune response against SARS-CoV-2.

    For information on the importance of targeting the ORF1ab region and the significance of T-cell immune response please read this publication:

    "Profound CD8 T cell responses towards the SARS-CoV-2 ORF1ab in COVID-19 patients" available HERE.

    Genetic Immunity first proposed targeting the ORF1ab region of SARS-CoV-2 in June of 2020. If your organization has an interest in exploring this trial please contact us.


    Proposed Trial Title Status


    Preclinical POC study to demonstrate SARS-CoV-2 specific immune response using our proprietary antigen specific pDNA construct. 

    Seeking Partner


    A Phase I/II, randomized, double-blind placebo controlled study to evaluate the safety, tolerability and Immunogenicity of Coviderm T-cell Immune therapy for the treatment of SARS-CoV-2 infection

    Seeking Partner